Trial · NCT03919799
Results by group1,768
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,768
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| DB Period: Number of Participants With Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score Greater Than or Equal to (>=) 60 Percent (%) at Week 24 | DB Period: Belumosudil QD | 6 | Participants | ||
| DB Period: Number of Participants With Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score Greater Than or Equal to (>=) 60 Percent (%) at Week 24 | DB Period: Belumosudil BID | 3 | Participants | ||
| DB Period: Number of Participants With Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score Greater Than or Equal to (>=) 60 Percent (%) at Week 24 | DB Period: Placebo | 7 | Participants | ||
| DB Period: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis Score at Week 24 | DB Period: Belumosudil QD | 14.30 | 95% Confidence Interval 9.47 to 19.12 | score on a scale | |
| DB Period: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis Score at Week 24 | DB Period: Belumosudil BID | 10.16 | 95% Confidence Interval 5.41 to 14.91 | score on a scale | |
| DB Period: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis Score at Week 24 | DB Period: Placebo | 14.34 | 95% Confidence Interval 10.04 to 18.64 | score on a scale | |
| OLE Period: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis Score at Week 52 | OLE Period: Belumosudil QD | 87.46 | Standard Deviation 27.376 | score on a scale | |
| OLE Period: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis Score at Week 52 | OLE Period: Placebo/Belumosudil QD | 7.16 | Standard Deviation 8.749 | score on a scale | |
| OLE Period: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis Score at Week 52 | OLE Period: Belumosudil BID | 64.37 | Standard Deviation 41.950 | score on a scale | |
| OLE Period: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis Score at Week 52 | OLE Period: Placebo/Belumosudil BID | 11.62 | Standard Deviation 19.282 | score on a scale | |
| DB Period: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 | DB Period: Belumosudil QD | -9.2 | 95% Confidence Interval -12.2 to -6.2 | score on a scale | |
| DB Period: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 | DB Period: Belumosudil BID | -4.0 | 95% Confidence Interval -7.0 to -1.0 | score on a scale | |
| DB Period: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 | DB Period: Placebo | -8.6 | 95% Confidence Interval -11.4 to -5.8 | score on a scale | |
| DB Period: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 24 | DB Period: Belumosudil QD | 0.6 | 95% Confidence Interval -4.0 to 5.2 | percent predicted FVC | |
| DB Period: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 24 | DB Period: Belumosudil BID | -2.3 | 95% Confidence Interval -7.2 to 2.5 | percent predicted FVC | |
| DB Period: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 24 | DB Period: Placebo | -0.8 | 95% Confidence Interval -5.2 to 3.6 | percent predicted FVC | |
| DB Period: Change From Baseline in Physician Global Assessment of Participant's Overall Health Using Visual Analogue Scale Score at Week 24 | DB Period: Belumosudil QD | 22.4 | 95% Confidence Interval 10.0 to 34.8 | score on a scale | |
| DB Period: Change From Baseline in Physician Global Assessment of Participant's Overall Health Using Visual Analogue Scale Score at Week 24 | DB Period: Belumosudil BID | -0.8 | 95% Confidence Interval -13.2 to 11.6 | score on a scale | |
| DB Period: Change From Baseline in Physician Global Assessment of Participant's Overall Health Using Visual Analogue Scale Score at Week 24 | DB Period: Placebo | 7.8 | 95% Confidence Interval -4.1 to 19.6 | score on a scale | |
| DB Period: Change From Baseline in Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale Score at Week 24 | DB Period: Belumosudil QD | -5.8 | 95% Confidence Interval -22.4 to 10.8 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03919799/results